|View printer-friendly version|
|August 07, 2001 11:35 a.m.|
|15 European Countries Agree to Approve Copaxone®|
INITIAL LAUNCHES SCHEDULED FOR FOURTH QUARTER 2001
Jerusalem, Israel, August 7, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Aventis Pharma AG, the pharmaceutical company of Aventis (NYSE: AVE) announced today that 15 European countries agreed to approve Copaxone® (glatiramer acetate) for the reduction in frequency of relapses in patients with relapsing-remitting multiple sclerosis. Copaxone® will be marketed in Europe by Teva Pharmaceuticals and Aventis Pharma.